NASDAQ NMS - GLOBAL MARKET · CGTX
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Cognition Therapeutics Inc

Cognition Therapeutics Inc

Pharmaceuticals
$0.9959
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
CGTX
Cognition Therapeutics Inc
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

44/ 100
Veridion Score
SELL BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is CGTX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading CGTX catalysts
About Cognition Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2021
Employees
14
Country
US

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.9959
Last session
Day high
$0.9959
Last session
Day low
$0.9959
Last session
Previous close
$0.9959
52W high
$3.18
-68.68% from high
52W low
$0.5946
16% of range
Market cap
$94.7M
EPS
$-0.2600
Beta
1.38
Shares out
95.1M
Avg volume
657.9K
VWAP
$0.9959
Last session
Price history computed in-house
1W
-2.36%
1M
+8.31%
3M
-19.69%
1Y
-64.56%
YTD
-26.23%
SMA 50 $1.08 · below
SMA 200 $1.22 · below
52W position 16%

CGTX overview

Veridion Score
44
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around CGTX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading CGTX Form 4 filings
Public disclosures

Congress activity in CGTX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for CGTX in the cached public ledger.

Federal contracts

CGTX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CGTX in this window.
Lobbying spend

CGTX lobbying filings, year to date.

Registered lobbying filings matched to Cognition Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CGTX in this window.
Loading news for CGTX
Analyst ratings
Sovereign unlock shows live analyst consensus for CGTX.
Options
Sovereign unlock shows live options positioning for CGTX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.